Advertisement
Clinical Therapeutics
Advanced searchSave search
Research Article| Volume 19, ISSUE 2, P232-242, March 1997

Loratadine in the treatment of urticaria

DOI:https://doi.org/10.1016/S0149-2918(97)80112-9
Loratadine in the treatment of urticaria
Previous ArticleThe nonnarcotic antitussive drug dimemorfan: a review
Next ArticleEfficacy and tolerability of finasteride in symptomatic benign prostatic hyperplasia: a primary care study
      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      Urticaria is a common skin disease, which, in its chronic form, is a very disturbing condition. Because histamine is the best-documented chemical mediator of urticaria, histamine1-antagonists are the mainstay of therapy. First-generation anti-histamines are limited by their tendency to produce sedation and anticholinergic side effects. Most of the newer second-generation antihistamines compare well with the earlier agents in efficacy but are not limited by the same adverse side effects. Loratadine may be distinguished from other second-generation antihistamines by its pharmacodynamics profile, as well as its tolerability and safety.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Belaich S
        • Bruttmann G
        • DeGreef H
        • et al.
        Comparative effects of loratadine and terfenadine in the treatment of chronic idiopathic urticaria.
        Ann Allergy. 1990; 64: 191-194
        • Schafer T
        • Ring J
        Epidemiology of urticaria.
        in: Burr ML Epidemiology of Clinical Allergy. Karger, Basel1993: 49-60
        • Greaves MW
        Chronic urticaria.
        NEJM. 1995; 332: 1767-1772
        • Mahmood T
        Urticaria.
        Am Fam Physician. 1995; 51: 811-816
        • Ortolani C
        • Ispano M
        Foods and chronic urticaria.
        Clin Rev Allergy. 1992; 10: 325-347
        • Ormerod AD
        Urticaria: Recognition, causes and treatment.
        Drugs. 1994; 48: 717-730
        • Kaplan AP
        • Gray L
        • Shaff RE
        • et al.
        In vivo studies of mediator release in cold urticaria and cholinergic urticaria.
        J Allergy Clin Immunol. 1975; 55: 394-402
        • Kaplan AP
        • Horokova Z
        • Katz SI
        Assessment of tissue fluid histamine levels in patients with urticaria.
        J Allergy Clin Immunol. 1978; 61: 350-354
        • Phanuphak P
        • Schocket AL
        • Arroyave CM
        • Kohler PF
        Skin histamine in chronic urticaria.
        J Allergy Clin Immunol. 1980; 65: 371-375
        • Simons FER
        • Simons KJ
        The pharmacology and use of H1-receptor-antagonist drugs.
        NEJM. 1994; 330: 1663-1670
        • Natbony SF
        • Phillips ME
        • Elias JM
        • et al.
        Histologic studies of chronic idiopathic urticaria.
        J Allergy Clin Immunol. 1983; 71: 177-183
        • Longley J
        • Duffy TP
        • Kohn S
        The mast cell and mast cell disease.
        J Am Acad Dermatol. 1995; 32: 545-561
        • Kreutner W
        • Chapman RW
        • Gulbenkian A
        • Siegel MI
        Antiallergic activity of loratadine, a non-sedating antihistamine.
        Allergy. 1987; 42: 57-63
        • Naclerio RM
        Effects of antihistamines on inflammatory mediators.
        Ann Allergy. 1993; 71: 292-295
        • Letari O
        • Miozzo A
        • Folco G
        • et al.
        Effects of loratadine on cytosolic Ca2+ levels and leukotriene release: Novel mechanisms of action independent of the anti-histamine activity.
        Eur J Pharmacol. 1994; 266: 219-227
        • Barenholtz HA
        • McLeod DC
        Loratadine: A nonsedating antihistamine with once-daily dosing.
        Ann Pharmacother. 1989; 23: 445-450
        • Katchen B
        • Cramer J
        • Chang M
        • et al.
        Disposition of 14C-SCH 29851 in humans.
        Ann Allergy. 1985; 55 (Abstract): 393
        • Hilbert J
        • Radwanski E
        • Weglein R
        • et al.
        Pharmacokinetics and dose proportionality of loratadine.
        J Clin Pharmacol. 1987; 27: 694-698
        • Radwanski E
        • Hilbert J
        • Symchowicz S
        • Zampaglione N
        Loratadine: Multiple dose pharmacokinetics.
        J Clin Pharmacol. 1987; 27: 530-533
        • Batenhorst RL
        • Batenhorst AS
        • Graves R
        • et al.
        Pharmacologic evaluation of loratadine (SCH 29851), chlorpheniramine and placebo.
        Eur J Clin Pharmacol. 1986; 31: 247-250
        • Kassem N
        • Roman J
        • Gural RP
        • et al.
        Effects of loratadine (SCH-29851) in suppression of histamine-induced skin wheals.
        Ann Allergy. 1988; 60: 505-507
        • Roman IJ
        • Kassem N
        • Gural RP
        • Herron J
        Suppression of histamine-induced wheal response by loratadine (SCH 29851) over 28 days in man.
        Ann Allergy. 1986; 57: 253-256
        • Simons FER
        • McMillan JL
        • Simons KJ
        A double-blind, single-dose, crossover comparison of cetirizine, terfenadine, loratadine, astemizole and chlorpheniramine versus placebo: Suppressive effects on histamine-induced wheals and flares during 24 hours in normal subjects.
        J Allergy Clin Immunol. 1990; 86: 540-547
        • Labrecque M
        • Ghezzo H
        • L'Archeveque J
        • et al.
        Duration of effect of loratadine and terfenadine administered once a day for one week on cutaneous and inhaled reactivity to histamine.
        Chest. 1993; 103: 777-781
        • Simons FER
        H1-receptor antagonists: Clinical pharmacology and therapeutics.
        J Allergy Clin Immunol. 1989; 84: 845-861
        • Juhlin L
        • Landor M
        Drug therapy for chronic urticaria.
        Clin Rev Allergy. 1993; 10: 349-369
        • Bernstein IL
        • Bernstein DI
        The efficacy and safety of loratadine in the management of chronic iodiopathic urticaria.
        J Allergy Clin Immunol. 1988; 81 (Abstract): 211
        • Guerra L
        • Vincenzi C
        • Marchesi E
        • et al.
        Loratadine and cetirizine in the treatment of chronic urticaria.
        J Eur Acad Dermatol Venereol. 1994; 3: 148-152
        • Monroe EW
        • Fox RW
        • Green AW
        • et al.
        Efficacy and safety of loratadine (10 mg once daily) in the management of iodiopathic chronic urticaria.
        J Am Acad Dermatol. 1988; 19: 138-139
        • Monroe EW
        Relative efficacy and safety of loratadine, hydroxyzine and placebo in chronic idiopathic urticaria and atopic dermatitis.
        Clin Ther. 1992; 14: 17-21
        • Monroe EW
        • Bernstein DI
        • Fox RW
        • et al.
        Relative efficacy and safety of loratadine, hydroxyzine, and placebo in chronic iodiopathic urticaria.
        Arzneim-Forsch Drug Res. 1992; 42: 1119-1121
        • Shareeah AMA
        Comparative efficacy of loratadine and terfenadine in the treatment of chronic idiopathic urticaria.
        Int J Dermatol. 1992; 31: 355-356
        • Mauracher EH
        • Riches DJ
        Comparative trial of two non-sedating antihistamines loratadine versus astemizole, in Chinese patients with chronic urticaria.
        Immunol Allergy Pract. 1992; 19: 223-229
        • Van Cauwenberge PB
        New data on the safety of loratadine.
        Drug Invest. 1992; 4: 283-291
        • Simons FER
        H1-receptor antagonists.
        Drug Saf. 1994; 10: 350-380
        • Roth T
        • Roehrs T
        • Koshorek G
        • et al.
        Sedative effects of antihistamines.
        J Allergy Clin Immunol. 1987; 80: 94-98
        • Adelsberg BR
        • D'Amico-Beadon A
        The effects of loratadine, diphenhydramine and placebo on worker productivity: Results of a double blind trial.
        J Allergy Clin Immunol. 1990; 85 (Abstract): 296
        • DeRoeck J
        • Cluydts R
        • Herman P
        Effects of antihistamines on daytime alertness.
        J Allergy Clin Immunol. 1990; 85 (Abstract): 179
        • Ramaekers JG
        • Uiterwijk MMC
        • O'Hanlon JF
        Effects of loratadine and cetirizine on actual driving and psychometric test performance, and EEG during driving.
        Eur J Clin Pharmacol. 1992; 42: 363-369
        • Herman D
        • Arnaud A
        • Dry J
        • et al.
        Efficacite clinique et tolerance de la Loratadine versus Cetirizine dans le traitement de la rhinite allergique saisonniere.
        Allerg Immunol. 1992; 24: 270-274
        • Zyrtec™
        51st ed. Physicians' Desk Reference®. Medical Economics Data Production Company, Montvale, NJ1997: 2053-2055
        • Neves-Pinto RM
        • Moreira Lima G
        • da Mota Teixeira R
        A double-blind study of the effects of loratadine versus placebo on the performance of pilots.
        Am J Rhinol. 1992; 6: 23-27
        • Oei HD
        Double-blind comparison of loratadine (SCH 29851), astemizole and placebo in hay fever with regard to onset of action.
        Ann Allergy. 1988; 61: 436-439
        • del Carpio J
        • Kabbash L
        • Turenne Y
        • et al.
        Efficacy and safety of loratadine (10 mg once daily), terfenadine (60 mg twice daily), and placebo in the treatment of seasonal allergic rhinitis.
        J Allergy Clin Immunol. 1989; 84: 741-746
        • Paris DG
        • Parente TF
        • Bruschetta HR
        • et al.
        Torsades de pointes induced by erythromycin and terfenadine.
        Am J Emerg Med. 1994; 12: 636-638
        • Smith SJ
        Cardiovascular toxicity of antihistamines.
        Otolaryngol Head Neck Surg. 1994; 111: 348-354
        • Nightingale SL
        Warnings issued on nonsedating antihistamines terfenadine and astemizole.
        JAMA. 1992; 268: 705-706
        • Woosley R
        • Darrow WR
        Analysis of potential adverse drug reactions—A case of mistaken identity.
        Am J Cardiol. 1994; 74: 208-209
        • Affrime MB
        • Lorber R
        • Danzig M
        Three month evaluation of electrocardiographic effects of loratadine in humans.
        J Allergy Clin Immunol. 1993; 91 (Abstract): 259
        • Hey JA
        • Del Prado M
        • Chapman RW
        • et al.
        Loratadine produces antihistamine activity without adverse CNS or cardiovascular effects in guinea pigs: Comparative studies with sedating and nonsedating H1 antihistamines.
        J Allergy Clin Immunol. 1994; 93 (Abstract): 163

      51. Data on file, Schering-Plough Research Institute, Kenilworth, New Jersey.

        • Kailasam V
        • Mathews KP
        Controlled clinical assessment of astemizole in the treatment of chronic idiopathic urticaria and angioedema.
        J Am Acad Dermatol. 1987; 16: 797-804
        • Chervinsky P
        • Georgitis J
        • Banov C
        • et al.
        Once daily loratadine versus astemizole once daily.
        Ann Allergy. 1994; 73: 109-113
        • Bateman DN
        • Rawlins MD
        Clinical pharmacology of astemizole.
        in: Astemizole: A New, Non-sedative, Long-Acting H1-Antagonist. Medicine Publishing Foundation, Oxford1984: 43-54
        • Skassa-Brociek W
        • Chanal I
        • Lemonier C
        • et al.
        Lack of subsensitivity to loratadine during a 12 week treatment.
        J Allergy Clin Immunol. 1990; 85 (Abstract): 238
        • Grant JA
        • Bernstein DI
        • Buckley CE
        • et al.
        Double-blind comparison of terfenadine, chlorpheniramine and placebo in the treatment of chronic idiopathic urticaria.
        J Allergy Clin Immunol. 1988; 81: 574-579
        • Kennard CD
        • Ellis CN
        Pharmacologic therapy for urticaria.
        J Am Acad Dermatol. 1991; 25: 176-189
        • Krause HF
        Therapeutic advances in the management of allergic rhinitis and urticaria.
        Otolaryngol Head Neck Surg. 1994; 111: 364-372
        • Goldsmith P
        • Dowd PM
        The new H1 antihistamines.
        Dermatol Ther. 1993; 11: 87-95
        • Monroe EW
        Urticaria and angioedema.
        in: Sams WM Lynch PJ Principles and Practice of Dermatology. Churchill Livingstone, New York1996: 521-534

      Article info

      Identification

      DOI: https://doi.org/10.1016/S0149-2918(97)80112-9

      Copyright

      © 1997 Published by Elsevier Inc.

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX